MiMedx at the 5th Congress of World Union Wound Healing Societies

MARIETTA, Ga., Sept. 29, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the highlights of the Company's participation in the 5^th Congress of World Union Wound Healing Societies ("WUWHS") held in Florence, Italy from September 25, 2016 through September 29, 2016.

MiMedx's presence at the WUWHS included educational sessions, a symposium, and presentations and poster abstracts delivered by independent physicians and researchers demonstrating the clinical effectiveness of the MiMedx EpiFix® and AmnioFix® dehydrated Human Amnion/Chorion Membrane (dHACM) and EpiCord™ dehydrated human umbilical cord allografts. The WUWHS is the most widely attended international symposium dedicated to wound healing with more than 4,500 physicians, research scientists and other healthcare professionals in attendance. The goals of the WUWHS are to: update and advance research and clinical skill in wound healing; compare cost-effectiveness of wound care among different countries to optimize reimbursement; strengthen collaboration among international representatives and design an appropriate long-term plan for wound care societies collaboration in order to exchange effective prevention and treatment goals.

Parker H. "Pete" Petit, CEO, said, "We are proud to be associated with the WUWHS, and we admire its goals and mission. We have diligently pursued similar domestic goals for the members of our industry, and we look forward to a long and prosperous relationship with the WUWHS by partnering with it in pursuit of its global wound care prevention and treatment goals. MiMedx has set an aggressive strategy to establish a significant presence in the international wound care markets, and our participation in the recent WUWHS is part of our on-going strategy to globally market the clinical and economic effectiveness of our dHACM allografts."

At the WUWHS, MiMedx sponsored a Lunch Symposium entitled, "The Dynamic Impact of EpiFix Amniotic Membrane Allografts." Chair of the lunch symposium, Severin Launchli, MD, spoke on "The Swiss Experience with EpiFix." Thomas Serena, MD, presented "The Scientific and Clinical Evidence of EpiFix dehydrated Human Amnion/Chorion Membrane (dHACM) Allografts." Matthew Garoufalis, DPM, presented "Application Techniques and Therapeutic Approaches Using EpiFix and AmnioFix Allografts for Wound Healing and Surgical Procedures."

Three poster abstracts reporting the clinical and cost effectiveness of EpiFix and AmnioFix dHACM allografts and EpiCord, one of MiMedx's newer products, were presented by Matthew Garoufalis, DPM. The abstracts, authored by Dr. Garoufalis, highlighted the results and independent case study conclusions. Dr. Garoufalis' abstracts included:

• "The Use of Dehydrated Umbilical Cord in the Successful Treatment of Chronic Wounds"
                                              
• "The Use of Injectable Micronized Amnion/Chorion Membrane in the Successful Treatment of Chronic Wounds"
                                      
• "Using Amniotic Membranes for Effective Wound Healing"

Bill Taylor, President and COO, commented, "Just as we have established a significant presence in the leading symposiums on wound care and other medical disciplines held in the United States, we will be following the same strategy with the leading symposiums and congresses hosted internationally. We are always excited to have the opportunity to showcase the outstanding clinical and economic effectiveness of our allografts."  

MiMedx conducted in-booth education throughout the duration of the WUWHS congress.

About EpiFix  
EpiFix is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix dHACM modulates inflammation and reduces scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix minimizes graft waste. EpiFix is a minimally manipulated, dehydrated non-variable cellular amniotic membrane allograft that preserves and delivers multiple extracellular matrix proteins, growth factors, cytokines and other specialty proteins present in amniotic tissue. The Company's PURION Process combines cleaning, dehydration and sterilization, making EpiFix a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About AmnioFix  
AmnioFix is a composite amniotic tissue membrane minimally manipulated to protect the collagen matrix and its natural properties. AmnioFix reduces scar tissue formation, modulates inflammation in the surgical site, enhances healing and acts as a barrier. AmnioFix is processed through the proprietary PURION Process that combines cleaning, dehydration and sterilization, and it may be stored at ambient conditions for up to 5 years. The proprietary PURION Process protects the delicate scaffold during processing, leaving an intact collagen matrix. The result is a durable graft with natural barrier properties to optimize surgical performance and ease of use. AmnioFix is available in sheet/membrane, particulate, and wrap configurations. 

About EpiCord  
EpiCord is a unique, thick membrane derived from umbilical cord, the structure that protects the arteries and vein that carry essential nourishment and oxygenated blood to and from mother and fetus. EpiCord is a minimally manipulated, dehydrated, non-viable cellular umbilical cord allograft for homologous use. EpiCord provides a protective environment for the healing process, and provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue. EpiCord is processed using the PURION® PLUS Process, a unique approach that provides an easy to use allograft stored at ambient conditions.

About MiMedx 
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix,  EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and  CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. 

We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement  
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Certain of the risks and uncertainties that could cause actual results to differ materially from such forward-looking statements include the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2015 and its most recent 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com